Kakei Yasumasa, Akashi Masaya, Komatsubara Hideki, Minamikawa Tsutomu, Komori Takahide
Department of Oral and Maxillofacial Surgery, Institute of Clinical Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
Head Neck Oncol. 2012 Jun 23;4:38. doi: 10.1186/1758-3284-4-38.
Secondary malignancy in the oral mucosa is recognized as one of the most serious complications in patients who received allogenic hematopoietic stem cell transplantation (HSCT). However, potential risk factors associated with carcinogenesis after HSCT that have been reported remain elusive. We experienced a rare case of secondary malignancies of the oral and esophageal mucosa and analyzed the expression of tumor suppressor gene product p16.
A 35-year-old male had malignant lesions of the oral and esophageal mucosa two years after HSCT. Partial maxillectomy and endoscopic submucosal dissection were performed. Immunohistochemical analyses revealed that the tumor cells of malignant and premalignant lesions of the oral cavity and esophagus but not keratosis were positive for p16.
Pathological examinations with p16 immunohistochemistry may contribute to an early diagnosis of secondary malignancy after HSCT.
口腔黏膜继发性恶性肿瘤被认为是接受异基因造血干细胞移植（HSCT）患者最严重的并发症之一。然而，已报道的与HSCT后致癌相关的潜在危险因素仍不明确。我们遇到了一例罕见的口腔和食管黏膜继发性恶性肿瘤病例，并分析了肿瘤抑制基因产物p16的表达。
一名35岁男性在HSCT两年后出现口腔和食管黏膜恶性病变。进行了部分上颌骨切除术和内镜黏膜下剥离术。免疫组织化学分析显示，口腔和食管恶性及癌前病变的肿瘤细胞（而非角化病）p16呈阳性。
p16免疫组织化学病理检查可能有助于HSCT后继发性恶性肿瘤的早期诊断。
